

REMARKS


Claims 2-6, 9, 12-17, and 24-30 are currently pending. Applicants cancel claims 1, 7, 8, 10, and 11 without prejudice or disclaimer. Allowable claims 2, 12, and 14 have been amended from dependent claims to independent claims to overcome Examiner's objections. Allowable claim 9 has been amended to depend on claim 2 to overcome Examiner's objections. Allowable claim 24 has been amended to overcome Examiner's rejection under 35 U.S.C. 112 providing antecedent basis to "fill port" in line 5. Claim 29 has been amended to correct its dependency based upon the above amendments. Allowance of the case with these amendments is hereby respectfully requested.

Fee Authorization

Should any extension of time and/or fee be necessary for timely submission of this paper, such extension of time is hereby requested, and the Commissioner is hereby authorized to charge **Deposit Account No. 01-2213 (order no. 4657)**. Any deficiency or overpayment should be charged or credited to this deposit account.

Date: March 14, 2005

Respectfully submitted,


Phil N. Makrogiannis
Reg. No. 47,766
Attorney for Applicants

CORRESPONDENCE ADDRESS

Customer Number: 22896
APPLERA CORPORATION
Applied Biosystems Group
Patent Department – M/S 432-2
850 Lincoln Centre Drive
Foster City, California 94404
TEL: 650-554-2164
FAX: 650-638-6677